Table 1.
Demographic, disease, and treatment characteristics
| Characteristic | Undetectable EOR PSA (N=206) |
Detectable EOR PSA (N=482) |
P-value |
|---|---|---|---|
|
| |||
| Median age (range), yrs | 68 (50–80) | 69 (49–82) | 0.07 |
|
| |||
| Africa-American race, n (%) | 40 (19) | 126 (26) | 0.06 |
|
| |||
| Initial PSA, ng mL−1 | 0.25 | ||
| <10, n (%) | 128 (62) | 318 (66) | |
| 10–20, n (%) | 54 (26) | 99 (21) | |
| >20, n (%) | 24 (12) | 65 (13) | |
|
| |||
| Gleason score | <0.001 | ||
| 3+3 | 84 (41) | 289 (60) | |
| 3+4 | 64 (31) | 80 (17) | |
| 4+3 | 17 (8) | 38 (8) | |
| 4+4 | 22 (11) | 30 (6) | |
| 4+5 | 14 (7) | 18 (4) | |
| 5+4 | 5 (2) | 8 (2) | |
| 5+5 | 0 (0) | 3 (1) | |
|
| |||
| T-stage, % | 0.001 | ||
| T1 | 81 (39) | 229 (48) | |
| T2 | 83 (40) | 205 (43) | |
| T3/T4 | 42 (20) | 48 (10) | |
|
| |||
| NCCN risk level | <0.001 | ||
| Low | 28 (14) | 214 (44) | |
| Intermediate | 91 (44) | 144 (30) | |
| High | 87 (42) | 124 (26) | |
|
| |||
| Perineural invasion on biopsy | 64 (31) | 71 (15) | <0.001 |
|
| |||
| Median radiation dose (range), cGy | 7380 (6840 – 7560) | 7200 (6480 – 7560) | <0.001 |
|
| |||
| Intensity modulated radiation therapy | 74 (36) | 107 (22) | <0.001 |
|
| |||
| Androgen deprivation therapy | <0.001 | ||
| None | 7 (3) | 287 (60) | |
| Neoadjuvant and concurrent only | 117 (57) | 101 (21) | |
| Neoadjuvant, concurrent, and adjuvant | 82 (40) | 94 (19) | |
Abbreviations: National Comprehensive Care Network (NCCN); prostate-specific antigen (PSA)